Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
2.030
-0.090 (-4.25%)
At close: Dec 20, 2024, 4:00 PM
2.130
+0.100 (4.93%)
After-hours: Dec 20, 2024, 4:16 PM EST
Immutep Revenue
In the fiscal year ending June 30, 2024, Immutep had annual revenue of 3.84M AUD with 9.59% growth. Immutep had revenue of 1.73M in the half year ending June 30, 2024, a decrease of -34.22%.
Revenue (ttm)
3.84M AUD
Revenue Growth
+9.59%
P/S Ratio
n/a
Revenue / Employee
123,932 AUD
Employees
31
Market Cap
309.27M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
Jun 30, 2020 | 13.74M | 8.10M | 143.72% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Viemed Healthcare | 214.30M |
AirSculpt Technologies | 188.78M |
Voyager Therapeutics | 163.78M |
Rigel Pharmaceuticals | 157.37M |
AVITA Medical | 60.04M |
Nyxoah | 5.67M |
Sera Prognostics | 94.00K |
IMMP News
- 4 days ago - Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewsWire
- 9 days ago - Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 - GlobeNewsWire
- 5 weeks ago - Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients - Seeking Alpha
- 5 weeks ago - Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial - Benzinga
- 5 weeks ago - Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer - GlobeNewsWire
- 7 weeks ago - Immutep Quarterly Activities Report Q1 FY25 - GlobeNewsWire
- 2 months ago - Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 2 months ago - Immutep: Navigating The Bumps In The Road - Seeking Alpha